[75]
Since there was no evidence to substantiate Novopharm's assertions that everything in the documents and information was confidential, Abbott says there was no evidence that any risk attached to disclosure of any such documents, and therefore there was no basis upon which to order any documents be included in a Protective Order.
Novopharm